Articles tagged with Ovarian Tumors
Researchers at UC San Diego found that ovarian cancer tumors activate FAK protein to regulate CD155 expression, creating a shield against immune detection and evading treatment. New molecular targets may boost immune response and lead to new combinatorial strategies for this disease.
The ATHENA-MONO trial shows significant improvements in progression-free survival for patients with advanced ovarian cancer treated with Rubraca as maintenance therapy. Benefit was observed across all patients, including those with homologous recombination deficiency and BRCA mutant tumors.
Researchers discovered that ovarian cancer tumors evade immune attack by redirecting tryptophan breakdown to the serotonin pathway, increasing NAD+ levels. Blocking this pathway with IDO1 inhibitors can be ineffective due to the adaptation of tumor microenvironments.
A meta-analysis of over 3,000 studies found that women with one ovary have a 30% lower chance of becoming pregnant and giving birth after IVF. The study suggests that surgical removal of an ovary has an adverse effect on fertility.
Researchers at the University of Helsinki found that a cellular stress state predicts a poor chemotherapy response in ovarian cancer patients. High-stress tumours with an inflammatory microenvironment may resist chemotherapy, making combination therapies a potential solution.
Researchers at the University of Helsinki discovered that tumour cells in ovarian cancer hide from the body's immune system by interacting with specific gene mutations. Tumours with BRCA1/2 mutations are more effectively targeted by killer T-cells, leading to better patient outcomes.
Investigators at Weill Cornell Medicine identified significant age-related differences in tumor characteristics across various cancers, suggesting potential for personalized treatment approaches. They found that tumors from younger patients showed advanced signs of aging and more mutations associated with aggressive disease.
Researchers at Hokkaido University analyzed hundreds of women with ovarian granulosa cell tumors to improve understanding of the disease progression and response to therapy. They found that early-stage tumors rarely spread beyond the ovaries, and fertility-sparing surgery may be considered for younger patients.
Scientists used single-cell sequencing to analyze over 150,000 cells from 11 tumor samples, discovering novel mechanisms of tumor development and identifying potential targets for therapy. The findings may lead to personalized medicine and improved treatment options for gynecologic cancers.
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
Researchers have identified metabolic signatures in blood plasma that can predict a patient's response to chemotherapy and prognosis. This discovery enables physicians to personalize treatment and enhance its efficiency, leading to improved outcomes for patients with gynecologic tumors.
A team of researchers has developed an ensemble-based machine learning model that can predict how cancer patients will respond to certain drugs with high accuracy. The model was trained on data from 499 independent cell lines and validated against a clinical dataset containing seven chemotherapeutic drugs.
Researchers at the University of Alabama at Birmingham have identified DOT1L as a potential therapeutic target for ovarian cancer. Inhibitors of the DOT1L enzyme showed promise in reducing tumor growth and improving survival rates by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
Researchers at Texas A&M University have developed an organ-on-a-chip that models the interaction between platelets and ovarian cancer tumors, revealing a crucial genetic signaling pathway. This breakthrough technology has potential applications in observing how cancer cells interact with blood vessels and testing novel treatments.
Researchers developed a new computational approach, CancerCellNet, to evaluate research models. The tool uses RNA sequences to compare lab-grown cancer cells with human tumor data, finding that cell lines are genetically inferior to genetically engineered mice and tumoroids in 4 out of 5 tested tumor types.
A study evaluating 22 patients with recurrent Anti-hormonal granulosa cell tumors found low-to-moderate FDG uptake and variable ERα/ERβ expression. FES-PET/CT showed promising results in identifying treatment-eligible patients, with stable tumor locations decreasing in size during anti-hormonal treatment.
Researchers at McMaster University have discovered a new approach to training immune cells to fight cancer, which has shown promising results in overcoming the hostile conditions found inside solid tumours. The modified natural killer cells were able to destroy advanced ovarian and lung cancer with high effectiveness.
A new study found percutaneous image guided needle based thermal ablation to be a safe and effective adjunctive therapy for local control of metastatic gynecologic cancers. Nearly 96% of patients achieved complete tumor response over 10 months, with low side effects.
A study found that metformin successfully reduced symptoms associated with tuberous sclerosis complex, including a 44% drop in seizure frequency and a 21% reduction in brain tumour size. Researchers believe this could improve quality of life for TSC patients.
Researchers developed a platform to derive comprehensive molecular profiles of tumours, enabling personalized therapy recommendations and expanded treatment options. The Tumor Profiler study analyzed 240 patients' tumour samples using advanced testing methods, providing insights into cellular diversity and treatment response.
A new advanced computing technique enables doctors to take fewer, more accurate tumour biopsies by combining computed tomography (CT) scans with ultrasound images. This method captures the patchwork of different cancer cell types within a tumour, critical for selecting the best treatment.
A study by Harvard Medical School scientists reveals a transient, cooperative interaction between ovarian cancer cells that allows nonmetastatic tumor cells to invade distant sites. The team identified amplified ERBB2 levels in a specific cell population, which was activated by amphiregulin, a signaling protein found in advanced ovaria...
A new study published in JNCI: Journal of the National Cancer Institute indicates that receiving assisted reproductive technology does not increase the risk women have for developing ovarian cancer. While fertility treatments may slightly increase borderline ovarian tumor risk, this association appears to be due to underlying patient c...
Scientists have created a 3D tumour model for ovarian cancer, which can mimic the way tumour cells grow and respond to chemotherapy drugs. The new model has the potential to improve understanding and treatment of the disease.
A study from Karolinska Institutet in Sweden found that women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, with most preserving natural fertility. The study also showed similar survival rates as those who underwent radical surgical cancer treatment.
Researchers from CU published a paper on ovarian cancer tumor composition changes during chemotherapy, revealing potential biomarkers for therapeutic response. The team aims to improve prediction of patient response to chemotherapy using multi-spectral immunohistochemistry and transcriptomics.
A CUNY ISPH study reveals that ovarian cancer grows and evolves continuously, with mixtures of subclones accumulating mutations. The findings challenge previous simplistic models of discrete subtypes, offering a clearer picture of tumor heterogeneity.
Researchers found that blocking the tumor-promoting protein MDM2 could boost immunotherapy's effectiveness by allowing immune cells to kill tumor cells more efficiently. The study also suggests that combining MDM2 inhibitors with immunotherapy may lead to improved treatment outcomes for patients whose tumors are predicted to undergo hy...
Researchers utilized a computational method to analyze the CDR3 regions of T-cell receptors from high-grade serous ovarian cancers. The study found that patients with low T-cell infiltration but diverse or focused repertoires had clinical outcomes similar to highly-infiltrated tumors. The authors identified the degree of divergence bet...
A study published in Oncotarget reports that adoptive cell therapy in combination with checkpoint inhibitors improves T cell fold expansion and increases CD8 T cell tumor reactivity in patients with late-stage metastatic ovarian cancer. The authors suggest that combination immunotherapy may be a way forward for this purpose.
Researchers develop new type of immunotherapy targeting macrophages in omental fat, which appears to reduce ovarian cancer spread and tumour growth. The study shows promise for improving treatment outcomes, but further testing is needed.
In aggressive colorectal cancers, a structural framework called cancer-associated fibroblasts helps tumors evade the immune system by expressing high levels of CD73, an immune checkpoint enzyme. CAFs create a self-serving process that amplifies their own CD73 expression, suppressing immune responses.
Researchers at MUSC and UCSD found that autophagy genes work against tumors in certain types of ovarian cancer. The study validated the role of BECN1 and LC3B as tumor suppressors, shedding light on their potential as targets for treatment.
Researchers mapped genomic changes throughout the human lifespan to create a timeline for cancer development. The study suggests that tumour progression may start years or even decades before diagnosis, providing a new window of opportunity for early detection and treatment.
Researchers developed a novel anti-CEACAM antibody for fluorescence visualization of colorectal tumors and metastases. The antibody targets multiple CEACAMs, which can lead to improved detection of tumor margins and metastases with variable expression of CEA.
A study found that APLN overexpression correlates with worsened prognosis in ovarian cancer patients treated with bevacizumab. The researchers also identified a distinct gene signature associated with resistance development, paving the way for new treatment strategies.
Researchers at Fred Hutchinson Cancer Center have successfully shrunk solid tumors using a thin metal mesh loaded with CAR T cells in preclinical models of ovarian cancer. The approach showed promising results, clearing tumors in 70% of treated mice within 20 days.
Research found that KLK6 overexpression induces HMGA2 expression in colon cancer cells, contributing to CRC progression and metastasis. High KLK6 scores were linked to disease recurrence, suggesting its potential role as a biomarker.
A new study links elevated levels of FAK to the survival of cancer stem cells and DNA repair in ovarian cancer tumors, making them resistant to platinum chemotherapy. Researchers found that FAK inhibition can improve treatment response in mice with chemo-resistant tumors.
Researchers have identified seven types of germ cell tumors, which are caused by failure of mechanisms that prevent spontaneous embryonal development. The new classification is valuable for future research, epidemiology, and clinical care, as it enables more reliable mapping of treatment sensitivity and resistances.
Researchers at Oregon State University have developed an improved technique for using magnetic nanoclusters to kill hard-to-reach tumors. The nanoclusters, which can reach temperatures in excess of 100 degrees Fahrenheit, were found to be effective in treating ovarian cancer and other types of cancer.
Researchers identified two key chemokines, CCL5 and CXCL9, as universally implicated in T cell infiltration across all solid tumors. Their simultaneous presence is a key requirement for the engraftment of T cells and establishment of 'hot tumors.'
Researchers have successfully used circulating tumor DNA to monitor patient responses and find targeted treatments for ovarian cancer. The technique can detect genomic alterations in late-stage cancers, even when biopsies are difficult or impossible, and identify poor-responding patients after chemotherapy.
Researchers identify nicotinamide N-methyltransferase (NNMT) as a key player in promoting metastasis of ovarian cancer cells. The study reveals that the stroma surrounding tumor cells, rather than the cancer itself, drives disease progression and poor outcomes.
Researchers at MIT have developed a novel fluorescence imaging system to improve surgery for ovarian cancer, enabling surgeons to detect and remove tumors as small as 0.3 millimeters. This technology has shown promising results in mice, with median survival rates 40% longer than those without image guidance.
Researchers at Johns Hopkins Medicine have uncovered the role of a neurotransmitter called N-acetyl-aspartyl-glutamate (NAAG) in the spread of aggressive cancers. NAAG is found to be more abundant in higher-grade cancers, making it a potential marker for tumor progression or regression during cancer therapy.
A study analyzing over 7,000 tumors and normal samples reveals two simple patterns related to NAD production, a biomolecule essential to metabolism. Cancer cells' reliance on specific pathways for NAD production can be exploited with targeted therapies, offering new avenues for treating cancer.
MIT researchers have developed a new optical imaging system called DOLPHIN that can detect tiny tumors deep within living tissue. The system uses near-infrared light and hyperspectral imaging to pinpoint fluorescent probes, allowing for earlier cancer diagnosis and potentially more effective treatment.
This study developed a personalized approach to inducing immunity against unique combinations of tumor neoantigens, resulting in higher CD8+ T-cell immunity and delayed tumor growth. The vaccine platform successfully killed tumor cells, slowed tumor progression, and prolonged survival in preclinical models.
A new photoacoustic imaging technique may help diagnose ovarian cancer at an early stage, improving survival rates. The technology uses transvaginal ultrasound and co-registered photoacoustic tomography to reveal information about tumor angiogenesis and blood oxygen saturation.
A University of Guelph study has found that opening up the blood vessels to an ovarian tumour can potentially improve the effectiveness of treatment. By creating a healthy blood supply, the tumour becomes more accessible to treatment, increasing success rates.
Researchers at UNIGE and HUG discovered that mucinous tumours of the ovary and pancreas originate from embryonic germ cells that migrate to reproductive organs. These cells can mistakenly stop in other organs, leading to cancer decades later.
The study identified a new class of drug-targets, called master regulators, which are rarely mutated in cancer patients. The algorithm predicted the same top drug for almost half of metastatic patients, leading to rapid FDA approval for a clinical trial.
Researchers have successfully replicated ovarian tumors inside chicken eggs, paving the way for patient-centred cancer treatment. The 'chicken egg tumour model' allows for rapid testing of anti-cancer drugs tailored to each patient's needs.
Researchers identified a link between ARID1a mutations and mismatch repair deficiency, which can render tumors susceptible to immune checkpoint blockade therapies. The study found that tumors with ARID1a mutations exhibited increased sensitivity to anti-PD-1 therapy, suggesting potential benefits for patients with these mutations.
The study shows that ST1-ADC selectively inhibits tumor cell proliferation and induces tumor cell death in both in vitro and in vivo ovarian cancer models. The data provide promising results for the development of new therapeutic options to treat ovarian cancer.
Researchers found tumors with PTEN loss are less likely to generate an immune response, suggesting PTEN levels can predict treatment outcome. The study's findings may improve personalized medicine for BRCA-deficient ovarian cancer patients.
A new type of cancer vaccine made from patients' own immune cells has yielded promising results in an initial clinical trial. The vaccine triggers a broad anti-tumor T-cell response, with half of the vaccinated patients showing signs of improved survival and one patient remaining disease-free for five years.
Researchers developed a novel personalized vaccine made from tumor tissue and immune cells, inducing potent immune responses in patients with recurrent ovarian cancer. The vaccine showed promise in extending overall survival and improving progression-free survival.
Researchers have developed a universal fluorescent probe that targets and stains cancer stem cells, a type of tumor-initiating cell. The probe, named TiY, demonstrates high selectivity towards these cells, which are believed to cause relapses after radiation and chemotherapy.